Myocarditis after BNT162b2 and mRNA-1273 Vaccination
Report describes 8 patients hospitalised with chest pain who were diagnosed with myocarditis (MC) within 2-4 days of receiving BNT162b2 or mRNA-1273 vaccine. Vigilance for MC after COVID-19 mRNA vaccination is advised; further research is required to understand long-term CV risks
Source:
Circulation
SPS commentary:
The researchers highlight the real incidence of acute myocarditis after mRNA COVID-19 vaccine appears to be extremely rare; the US Centers for Disease
Control Vaccine Adverse Event Reporting System received reports of chest pain in 5166 and myocarditis in 399 recipients of the BNT162b2 or mRNA-1273 vaccine, whereas more than 129 million individuals have been fully vaccinated with these two vaccines in US.
The European Medicines Agency's safety committee (PRAC) is continuing its assessment of reports of myocarditis and pericarditis in a small number of people following vaccination with COVID-19 vaccines. Currently, further analysis is needed to conclude whether there is a causal relationship with the vaccines, and PRAC is requesting additional data from the manufacturers.